Versant Ventures related stories
All articles and analysis
Boehringer Ingelheim buys Northern Biologics’ preclinical pipelineBoehringer Ingelheim has acquired the preclinical cancer antibody pipeline of Northern Biologics, a Toronto-based therapeutic antibodies affiliate of Northern LP.
Ventus Therapeutics snags Series AMassachusetts and Montreal-based Ventus Therapeutics Inc, a biopharmaceutical company, has secured US$60 million in Series A financing.
- Versant Ventures expands team and promotes staffers
Versant Ventures has made multiple promotions and appointments.
Canada's Amplitude more than halfway to final close on debut fundThe BDC spin-out has raised over half of the C$200 ($152 million) target for its first fund.
- HarbourVest closes second Canada growth fund
HarbourVest Partners has closed its second Canada growth fund at C$300 million. The fund was formed under the Canadian government's Venture Capital Catalyst Initiative. The fund's investors include institutional, corporate and high-net worth private sector investors from Canada, Europe and the U.S. As part of the VCCI program, the fund includes a cornerstone investment by the Canadian government through BDC Capital, the investment arm of BDC.
- Coda Biotherapeutics racks up funding
South San Francisco-based Coda Biotherapeutics Inc, a preclinical-stage biopharmaceutical company, has raised a total of $34 million in funding. Versant Ventures was the lead investor in Coda's latest funding round.
Toncheva promoted at USVP, Investor bails on Vision Fund, and a monthly recap of other VCs on the MoveA compilation of personnel moves from the previous four weeks at various firms, including USVP, Next Ventures and SoftBank
- Vida Ventures hires CFO/COO
Vida Ventures has named Jean-Philippe Kouakou-Zebouah as chief financial and chief operating officer. Previously, he worked at Versant Ventures where he was senior vice president of finance.
- VC-backed Aprea Therapeutics goes public
Boston and Stockholm-based Aprea Therapeutics, a clinical-stage biotechnology company developing novel anticancer therapies targeting the p53 tumor suppressor protein, has raised about $85 million for its IPO after pricing its over 5.6 million shares at $15 per share. The stock began trading October 3, 2019 on the NASDAQ under the ticker symbol "APRE." J.P. Morgan, Morgan Stanley and RBC Capital Markets are the lead underwriters. Aprea's pre-IPO backers include Redmile Group, Rock Springs Capital, 5AM Ventures, Versant Ventures, HealthCap, Sectoral Asset Management and Karolinska Development AB.